WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018031507) TREATMENT OF CANCER USING A COMBINATION OF IMMUNOMODULATION AND CHECK POINT INHIBITORS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/031507    International Application No.:    PCT/US2017/045823
Publication Date: 15.02.2018 International Filing Date: 08.08.2017
IPC:
A61K 31/00 (2006.01), A61K 31/39 (2006.01), A61K 39/00 (2006.01), A61K 39/395 (2006.01), C07K 16/28 (2006.01)
Applicants: ANGIMMUNE, LLC [US/US]; 9624 Parkwood Drive Bethesda, MD 20814-4024 (US)
Inventors: NEVILLE, David M.; (US)
Agent: WHITHAM, Michael E.; (US).
FIELDS, Whitney, C.; (US).
TYLER-CROSS, Ruth, E.; (US).
CURTIS, Marshall, M.; (US)
Priority Data:
62/372,444 09.08.2016 US
Title (EN) TREATMENT OF CANCER USING A COMBINATION OF IMMUNOMODULATION AND CHECK POINT INHIBITORS
(FR) TRAITEMENT DU CANCER À L'AIDE D'UNE COMBINAISON D'INHIBITEURS D'IMMUNOMODULATION ET DE POINT DE CONTRÔLE
Abstract: front page image
(EN)Methods of treating patients suffering from cancer using a combination of 1) an immunomodulatory agent; 2) a check point inhibitor; and 3) a cancer antigen releasing therapy are provided. In some aspects, the immunomodulatory agent is an anti-CD3 immunotoxin, the check point inhibitor inhibits the interaction of PD-1 and PD-L1 and the cancer antigen releasing therapy is radiation.
(FR)L'invention concerne des méthodes de traitement de patients souffrant d'un cancer à l'aide d'une combinaison de 1) un agent immunomodulateur ; 2) un inhibiteur de point de contrôle ; et 3) une thérapie de libération d'antigène du cancer. Dans certains aspects, l'agent immunomodulateur est une immunotoxine anti-CD3, l'inhibiteur de point de contrôle inhibe l'interaction de PD-1 et PD-L1 et la thérapie de libération d'antigène du cancer est un rayonnement.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)